Featured Publications
Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials
Oikonomou EK, Spatz ES, Suchard MA, Khera R. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials. The Lancet Digital Health 2022, 4: e796-e805. PMID: 36307193, PMCID: PMC9768739, DOI: 10.1016/s2589-7500(22)00170-4.Peer-Reviewed Original ResearchConceptsSystolic blood pressure controlBlood pressure controlIntensive systolic blood pressure controlType 2 diabetesPressure controlCardiovascular benefitsClinical trialsMajor adverse cardiovascular eventsFirst major adverse cardiovascular eventLarge randomised clinical trialsACCORD-BP trialAdverse cardiovascular eventsRandomised clinical trialsSystolic blood pressureCox regression analysisTreatment effectsHazard ratio estimatesACCORD-BPBP trialCardiovascular eventsBlood pressurePrimary outcomeStandard treatmentBaseline variablesIndex patients
2021
Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States
Sangha V, Lipska K, Lin Z, Inzucchi SE, McGuire DK, Krumholz HM, Khera R. Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States. Circulation Cardiovascular Quality And Outcomes 2021, 14: e008381. PMID: 34779654, PMCID: PMC9022137, DOI: 10.1161/circoutcomes.121.008381.Peer-Reviewed Original ResearchConceptsType 2 diabetesMedicare beneficiariesSodium-glucose cotransporter 2 inhibitorsLarge randomized clinical trialsMedicare Part D prescriber dataChronic kidney diseaseCotransporter 2 inhibitorsAtherosclerotic cardiovascular diseasePercent of cliniciansRandomized clinical trialsUS Medicare beneficiariesAdvanced practice providersCross-sectional studyKidney outcomesSGLT2i useSulfonylurea prescriptionUnique cliniciansCardiovascular deathMedication classesKidney diseaseLabel indicationsClinical trialsSGLT2iCardiovascular diseasePractice providersContemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes
Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes. Journal Of The American Heart Association 2021, 10: e021084. PMID: 33998258, PMCID: PMC8403287, DOI: 10.1161/jaha.121.021084.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2Drug UtilizationEligibility DeterminationFemaleGlucagon-Like Peptide-1 ReceptorGuideline AdherenceHeart Disease Risk FactorsHumansIncretinsMaleMiddle AgedNutrition SurveysPractice Guidelines as TopicPractice Patterns, Physicians'Risk AssessmentSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeUnited StatesConceptsSGLT-2 inhibitorsType 2 diabetes mellitusAtherosclerotic cardiovascular diseaseChronic kidney diseaseLarge clinical trialsGLP-1RAsDiabetes mellitusCardiovascular diseaseHeart failureKidney diseaseClinical trialsHigh-risk atherosclerotic cardiovascular diseaseGLP-1RA useAmerican Diabetes AssociationNutrition Examination SurveyAnti-hyperglycemic agentsPublic health benefitsComplex survey designCardiovascular riskGuideline recommendationsDiabetes AssociationExamination SurveyProtective therapyNational HealthAmerican College
2019
Targeted temperature management for cardiac arrest
Mody P, Kulkarni N, Khera R, Link MS. Targeted temperature management for cardiac arrest. Progress In Cardiovascular Diseases 2019, 62: 272-278. PMID: 31078561, DOI: 10.1016/j.pcad.2019.05.007.Peer-Reviewed Original ResearchConceptsHospital sudden cardiac arrestSudden cardiac arrestTemperature managementCardiac arrestSurvivors of SCAInitial shockable rhythmTargeted temperature managementInitial clinical trialsNon-shockable rhythmCore body temperatureTherapeutic hypothermiaDuration of coolingNeurological functionShockable rhythmPatient populationClinical trialsCurrent guidelinesNeurological damageCurrent evidenceSevere hypoxiaSurvivorsBody temperatureReview articleArrestSignificant improvement
2016
Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis
Dulai PS, Singh S, Marquez E, Khera R, Prokop LJ, Limburg PJ, Gupta S, Murad MH. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. The BMJ 2016, 355: i6188. PMID: 27919915, PMCID: PMC5137632, DOI: 10.1136/bmj.i6188.Peer-Reviewed Original ResearchConceptsLow-dose aspirinNon-aspirin NSAIDsMetachronous neoplasiaDose aspirinColorectal neoplasiaColorectal cancerChemoprevention agentsSystematic reviewCandidate agentCandidate chemoprevention agentsMetachronous colorectal cancerHigh-dose aspirinPrimary efficacy outcomeSerious adverse eventsEfficacy of agentsQuality of evidenceWeb of ScienceEfficacy outcomesAdverse eventsFavorable riskSafety profileBenefit profileClinical trialsGRADE criteriaSafety outcomesAssociation of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA 2016, 315: 2424-2434. PMID: 27299618, PMCID: PMC5617638, DOI: 10.1001/jama.2016.7602.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdverse eventsClinical trialsWeight lossObese adultsHigher oddsAdverse event-related treatment discontinuationSystematic reviewSignificant excess weight lossCumulative ranking (SUCRA) probabilitiesDiscontinuation of therapyExcess weight lossProportion of patientsManagement of obesityQuality of evidenceWeight loss agentsWeb of ScienceTreatment discontinuationCochrane CENTRALPharmacological treatmentMagnitude of decreaseGRADE criteriaDrug treatmentLiraglutideMAIN OUTCOMEPlacebo participants